The Prevalence of Hypomagnesemia in Hospitalized Type 2 Diabetic Patients Treated with Diuretics and/or Proton Pump Inhibitors

• Published in: The Israel Medical Association journal Vol. 23; no. 4; pp. 245 - 250
• Main Authors: Mengesha, Bethlehem, Levi, Daniela, Kroonenberg, Moran, Koren, Ronit, Golik, Ahuva, Koren, Shlomit
• Format: Journal Article
• Language: English
• Published: Israel 01.04.2021
• Subjects: Aged; Calcium - blood; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diuretics - administration & dosage; Diuretics - adverse effects; Female; Hospitalization - statistics & numerical data; Humans; Israel - epidemiology; Kidney Failure, Chronic - diagnosis; Kidney Failure, Chronic - epidemiology; Magnesium - blood; Male; Metabolic Diseases - diagnosis; Metabolic Diseases - epidemiology; Metabolic Diseases - etiology; Metabolic Diseases - metabolism; Middle Aged; Prevalence; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Israel
• ISSN: 1565-1088

Hypomagnesemia (serum magnesium level < 1.7 mg/dl) occurs more frequently in patients with type 2 diabetes mellitus (T2DM).Serum magnesium levels are not routinely tested in hospitalized patients, including in hospitalized patients with T2DM. To evaluate the prevalence of hypomagnesemia among hospitalized T2DM patients treated with proton pump inhibitors (PPIs) and/or diuretics. A total of 263 T2DM patients hospitalized in general departments were included in the study and were further divided into four groups: group 1 (patients not treated with PPIs or diuretics), group 2 (patients treated with PPIs), group 3 (patients treated with diuretics), and group 4 (patients treated with both PPIs and diuretics).  Blood and urine samples were taken during the first 24 hours of admission. Electrocardiogram was performed on admission. Of the 263 T2DM patients, 58 (22.1%) had hypomagnesemia (serum magnesium level < 1.7 mg/dl). Patients in group 2 had the lowest mean serum magnesium level (1.79 mg/dl ± 0.27). Relatively more patients with hypomagnesemia were found in group 2 compared to the other groups, although a statistically significant difference was not observed. Significantly more patients in group 3 and 4 had chronic renal failure. Patients with hypomagnesemia had significantly lower serum calcium levels. Hospitalized T2DM patients under PPI therapy are at risk for hypomagnesemia and hypocalcemia.